skip to Main Content

What Wayne Gretzky taught me about business in 20 minutes

Editor’s note: We don’t usually post personal essays on MI’s website, but we couldn’t pass on this one. Whether you’re a hockey fan or an entrepreneur looking for a fresh business perspective, we hope you’ll agree.

Last Wednesday, I was meeting an old friend for lunch in downtown Toronto. We’re both from Edmonton; we were classmates at the International Space University in Strasbourg, France. And we’re hockey fans. So I said, “Let’s have lunch at Wayne Gretzky’s.”

We didn’t expect to meet Wayne himself, but that’s what happened. One minute I was eating fish tacos. The next minute, my friend’s pointing with his fork: “Dude, Wayne Gretzky’s right behind you.”

Wayne Gretzky (centre) and MI's Hassan Jaferi (right) with X.
Wayne Gretzky (centre) and MI’s Hassan Jaferi (right) with Matthew Killick.

I was in Grade 2 when Gretzky’s Edmonton Oilers won the Stanley Cup in 1987. One of my classmates was the daughter of Andy Moog, the team goalie. He brought the cup into class after the Oilers won so we could all touch it. I grew up playing street hockey in Edmonton and idolizing Wayne. We all did.

So you’ll understand that we had to stop him and say hi. We just had to.

And then we were stunned when he put his glass down on our table and spent 20 minutes talking to us about his various business activities.

My hands were shaking as we left the restaurant an hour later. But here’s five things I managed to take away from this surreal and wonderful experience.

Continue Reading

MI’s Fanny Sie to speak about 3D printing trends at two Toronto events

Fanny-Sie-web-7227
Fanny Sie is a manager in MI’s Technology & Venture Development group and head, Imaging Technologies Area.

Fanny Sie, MaRS Innovation’s head of imaging technologies and a manager in the Technology & Venture Development group, is speaking about bioprinting trends at two Toronto conferences this weekend.

Sie is MI’s commercialization lead on the Bioprinter, a licensenable technology from the University of Toronto and Sunnybrook Health Sciences Centre.

Watch her interview on bioprinting with TVO’s The Agenda, which aired in June 2013.

First up is Digifest, an international festival celebrating digital creativity, which runs from May 8 to 10 at the Corus Quay building on Toronto’s Waterfront. Sie will speak about 3D printing and its biological and commercial implications on the Mass Customization Panel Discussion, which runs from 2 to 3 pm on Friday, May 9.

On Monday, Sie joins the opening panel at the OCE Discovery Conference, which runs from May 12 to 13, 2014 at the Metro Toronto Convention Centre (South Building). She will speak during the “3D Manufacturing: Beyond the Hype” panel at 9 am on May 13.

Continue Reading

MaRS Innovation Announces Collaboration with Johnson & Johnson Innovation

Collaboration will advance early-stage technologies and identify high-potential opportunities related to human health

MaRS Innovation logoTORONTO, Nov. 25, 2013 – MaRS Innovation (MI), a Centre of Excellence for Commercialization and Research, today announced a new collaboration with Johnson & Johnson Innovation and its affiliate Janssen, Inc., in Canada to advance early-stage technologies related to human health in therapeutics, medical devices, and diagnostics.

This announcement was covered by Biotechnology Focus and the Village Gamer blog.

Through the collaboration, MaRS Innovation and technical experts from the Johnson & Johnson Innovation Center in Boston, Massachusetts will jointly identify and fund high-potential opportunities emerging from well-validated scientific research discoveries within MaRS Innovation’s 16 member institutions, which include the University of Toronto and its affiliated teaching hospitals.

Raphael Hofstein, president and CEO MaRS Innovation
Dr. Raphael Hofstein, president and CEO of MaRS Innovation.

“We are looking forward to working with Johnson & Johnson Innovation,” said Dr. Raphael Hofstein, president and CEO, MaRS Innovation. “There are many high quality opportunities coming out of the Toronto research community, and these opportunities can benefit from our close collaboration.”

Through the agreement, Johnson & Johnson Innovation will provide funding over a three-year period to support promising individual projects based on joint due diligence, which will be leveraged with financial support from MaRS Innovation.

Continue Reading

ChipCare, UTEST and MaRS Innovation profiled in Nature journal article on commercialization programs in Canada

Canadian commercialization and entrepreneurial programs helping scientists and researchers bring their products to market are the focus of a recent article in Nature Journal and on nature.com.

Posted online on October 2, 2013, the article explains how the Centres of Excellence in Commercialization and Research (CECR) programme, and specifically MaRS Innovation, develop research and put it into practice:

MaRS Innovation's commercialization process
MaRS Innovation’s commercialization process: Bridging the gap between brilliant research and successful start-up companies or licensable technologies.

“MARS Innovation and its sister organization MARS Discovery District are not-for-profit organizations that are tightly integrated in Canadian research commercialization. They are based in a heritage building that once belonged to the Toronto University Hospital, in the heart of the city’s ‘discovery district’ — the inner-city conglomeration of universities, institutes and hospitals which has a reputation as a research hotbed. “Here, all the different actors in the commercialization sphere come together in one space,” says Ilse Treurnicht, CEO of MARS Discovery District.

Continue Reading

Bringing mad science to mass production: Financial Post features the Bio Printer project

University of Toronto PhD student Lian Len with a prototype tissue printer. Photo courtesy of Dominic Ali (University of Toronto)
University of Toronto PhD student Lian Len with a prototype tissue printer. Photo courtesy of Dominic Ali (University of Toronto)

“It’s one thing to invent a machine that prints skin, but it’s a whole other challenge to bring what seems like the domain of mad science to mass production,” Matthew Braga wrote in  “Looking for ways to get ‘skin’ in the game,” published in the Financial Post on July 15.

The article focuses on MaRS Innovation’s (MI) and the Innovations and Partnerships Office’s (University of Toronto) joint efforts to commercialize the bio printer, a “prototype 3D printer that, instead of extruding layers of plastic and other inorganic materials into physical shapes, builds layer upon layer of cell-laden tissue, a process that could lead to the cheap, rapid production of human skin.”

Braga’s article was syndicated in the Regina Leader Post, the Saskatoon Star-Phoenix,  and the Vancouver Sun, among other Canadian publications.

Continue Reading

MI’s Fanny Sie and Shotlst Founder Matt Ratto to appear on TVO’s The Agenda 8 pm

Fanny Sie, project manager, MaRS Innovation
Fanny Sie, project manager in physical sciences and medical devices , MaRS Innovation.

MaRS Innovation’s Fanny Sie, project manager in physical sciences and medical devices with specialization in medical imaging, is appearing on TVO’s The Agenda with Steve Paikin at 8 pm on June 5, 2013 to discuss 3D printing and the technology’s applications in healthcare and other aspects of human society.

Sie manages the Bioprinter technology, which was invented by Axel Guenther, a professor in the University of Toronto’s Department of Mechanical and Industrial Engineering, PhD student Lian Leng and a team of other researchers. The Globe and Mail covered the Bioprinter’s development on January 20, 2013.

Continue Reading

National Post: How does Canada solve its commercialization conundrum?

Government has key role to play as early-stage technology adopter says CEO Raphael Hofstein

Dr. Raphael Hofstein
Dr. Raphael Hofstein, president & CEO, MaRS Innovation.

Dr. Raphael Hofstein, president and CEO of MaRS Innovation, was quoted in Mary Theresa Bitti‘s National Post article, “Commercialization Conundrum: Canada must turn ideas into social and economic value,” published April 3, 2013.

The article examines Canada’s worsening track record in realizing commercialization gains based on the country’s significant per-capita investment in R&D.

Here’s an excerpt:

While Canada punches above its weight class when it comes to generating ideas — witness countless academic journals showcasing Canadian research — as a country, we are experiencing a failure to launch when it comes to commercializing those ideas and getting them to market. The Jenkins panel report on innovation spelled it out quite clearly, “Too many of the big ideas [Canada] generates wind up generating wealth for others.” Canada ranks 14th out of 17 peer countries when it comes to innovation, even though on a per-capita basis, our $7-billion federal annual investment into research and development (R&D) is far more generous than other OECD nations. The result: Our global competitiveness continues to slide. According to the World Economic Forum, Canada has dropped to 14th place in 2012 from 10th in 2010.

Continue Reading
Back To Top